Epilepsy is the fourth most common neurological disorder in the world1, affecting over 68 million people globally, and approximately 2.2 million people in the US2. In pediatric populations, it is estimated that about 470,000 US children under the age of 14 have epilepsy1. However, developing anti-seizure medications for pediatric patients has long been a challenge due…
Expertise: Neuroscience 32 results
Qualitative exit interviews are emerging as a valuable addition to clinical trials for central nervous system (CNS) disorders like schizophrenia, offering crucial insights into patient and caregiver experiences for sponsors, regulators, and others involved in the development, approval, and commercialization of new treatments. While symptom scales and other quantitative tools remain essential, they can miss…
Every October 10th, the world comes together to recognize World Mental Health Day, an initiative led by the World Health Organization (WHO) to raise awareness, break stigma, and promote mental well-being globally. To celebrate the day, we sat down with Adam Simmons, Premier’s Vice President, Program Strategy, Neuroscience, who is an industry veteran and leading…
Neuroscience
Jessica Hughes
Approximately 350 million people around the world live with major depressive disorder (MDD). While there are existing treatments, up to two-thirds of patients with MDD do not achieve remission following an initial adequate trial of antidepressant medications and nearly 70% experience residual symptoms with first line standard of care.1 There remains a critical need for…